Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Atara BiotherapeuticsAlectorImmunovantForma TherapeuticsVaxcyte
SymbolNASDAQ:ATRANASDAQ:ALECNASDAQ:IMVTNASDAQ:FMTXNASDAQ:PCVX
Price Information
Current Price$13.78$16.91$15.33$27.08$20.11
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.41.31.81.81.7
Analysis Score3.43.54.53.53.5
Community Score2.82.43.73.22.9
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.81.71.7
Earnings & Valuation Score0.60.00.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$35.88$33.67$45.60$61.67$48.00
% Upside from Price Target160.34% upside99.09% upside197.46% upside127.72% upside138.69% upside
Trade Information
Market Cap$1.15 billion$1.38 billion$1.54 billion$1.15 billion$1.04 billion
Beta2.651.08N/AN/AN/A
Average Volume880,357643,2971,506,142481,427417,666
Sales & Book Value
Annual RevenueN/A$21.22 millionN/A$100.56 millionN/A
Price / SalesN/A63.42N/A11.08N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.37 per share$2.83 per share$1.45 per shareN/AN/A
Price / BookN/A5.98N/AN/A
Profitability
Net Income$-290,980,000.00$-105,390,000.00$-66,390,000.00$-34,790,000.00$-50,270,000.00
EPS($5.67)($1.71)($1.54)N/AN/A
Trailing P/E RatioN/AN/AN/A0.000.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-757.78%N/AN/AN/A
Return on Equity (ROE)-94.86%-53.86%-34.80%-29.54%N/A
Return on Assets (ROA)-82.17%-31.44%-32.38%-20.61%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio9.41%6.61%35.15%13.55%10.12%
Quick Ratio9.41%6.61%35.15%13.55%10.12%
Ownership Information
Institutional Ownership PercentageN/A61.50%40.21%67.28%74.08%
Insider Ownership Percentage4.30%13.90%0.24%N/AN/A
Miscellaneous
Employees429162428958
Shares Outstanding83.62 million79.58 million97.97 million41.16 million51.33 million
Next Earnings Date5/5/2021 (Estimated)5/12/2021 (Estimated)7/5/2021 (Estimated)6/29/2021 (Estimated)7/5/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Vaxcyte, Inc. (NASDAQ:PCVX) Forecasted to Post FY2021 Earnings of ($1.81) Per ShareVaxcyte, Inc. (NASDAQ:PCVX) Forecasted to Post FY2021 Earnings of ($1.81) Per Share
americanbankingnews.com - April 2 at 8:36 AM
FY2021 EPS Estimates for Vaxcyte, Inc. (NASDAQ:PCVX) Reduced by Cantor FitzgeraldFY2021 EPS Estimates for Vaxcyte, Inc. (NASDAQ:PCVX) Reduced by Cantor Fitzgerald
americanbankingnews.com - April 1 at 8:16 AM
Vaxcyte, Inc. Expected to Post Q1 2021 Earnings of ($0.41) Per Share (NASDAQ:PCVX)Vaxcyte, Inc. Expected to Post Q1 2021 Earnings of ($0.41) Per Share (NASDAQ:PCVX)
americanbankingnews.com - April 1 at 6:52 AM
Vaxcyte IncVaxcyte Inc
reuters.com - March 31 at 6:00 AM
Vaxcyte (NASDAQ:PCVX) Shares Gap Down  on Insider SellingVaxcyte (NASDAQ:PCVX) Shares Gap Down on Insider Selling
americanbankingnews.com - March 30 at 10:40 AM
Vaxcyte (NASDAQ:PCVX) Posts Quarterly  Earnings Results, Beats Expectations By $0.13 EPSVaxcyte (NASDAQ:PCVX) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS
americanbankingnews.com - March 30 at 7:24 AM
Vaxcyte, Inc. (NASDAQ:PCVX) VP Sells $113,430.00 in StockVaxcyte, Inc. (NASDAQ:PCVX) VP Sells $113,430.00 in Stock
americanbankingnews.com - March 29 at 7:40 PM
Vaxcyte asks chairman Slaoui to step down after GSK harassment claimVaxcyte asks chairman Slaoui to step down after GSK harassment claim
finance.yahoo.com - March 25 at 7:35 AM
UPDATE 1-Vaxcyte asks chairman Slaoui to step down after GSK harassment claimUPDATE 1-Vaxcyte asks chairman Slaoui to step down after GSK harassment claim
finance.yahoo.com - March 25 at 7:35 AM
Sexual harassment claim leads to firing of former Operation Warp Speed chief. Will it impact his other board posts?Sexual harassment claim leads to firing of former Operation Warp Speed chief. Will it impact his other board posts?
bizjournals.com - March 24 at 7:26 PM
Vaxcyte (NASDAQ:PCVX) Shares Gap Down  After Insider SellingVaxcyte (NASDAQ:PCVX) Shares Gap Down After Insider Selling
americanbankingnews.com - March 24 at 11:10 AM
Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $386,550.00 in StockVaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $386,550.00 in Stock
americanbankingnews.com - March 23 at 10:44 PM
Vaxcyte (PCVX) to Release Quarterly Earnings on MondayVaxcyte (PCVX) to Release Quarterly Earnings on Monday
americanbankingnews.com - March 23 at 10:20 AM
Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021
feeds.benzinga.com - March 22 at 4:28 PM
We Think Vaxcyte (NASDAQ:PCVX) Can Easily Afford To Drive Business GrowthWe Think Vaxcyte (NASDAQ:PCVX) Can Easily Afford To Drive Business Growth
finance.yahoo.com - March 15 at 2:49 PM
Peninsula vaccine maker lands lease at big Alexandria projectPeninsula vaccine maker lands lease at big Alexandria project
bizjournals.com - January 26 at 6:36 PM
Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep InfectionsVaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections
finance.yahoo.com - January 6 at 2:31 PM
Vaxcyte Promotes Andrew Guggenhime to President and Chief Financial OfficerVaxcyte Promotes Andrew Guggenhime to President and Chief Financial Officer
finance.yahoo.com - December 22 at 1:16 PM
Is PCVX A Good Stock To Buy Now?Is PCVX A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 8:42 PM
U.S. IPO Week Ahead: DoorDash And Airbnb Kick Off The Unicorn Parade In A 6 IPO WeekU.S. IPO Week Ahead: DoorDash And Airbnb Kick Off The Unicorn Parade In A 6 IPO Week
seekingalpha.com - December 6 at 4:14 PM
IPO Calendar: December 7 - 11, 2020IPO Calendar: December 7 - 11, 2020
thestreet.com - December 5 at 11:23 PM
Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx ConferenceVaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference
finance.yahoo.com - November 24 at 7:07 PM
Vaxcyte to Present at Jefferies Virtual London Healthcare ConferenceVaxcyte to Present at Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 10 at 5:31 PM
We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To GrowWe're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow
finance.yahoo.com - September 14 at 2:46 PM
Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare ConferenceVaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 10 at 10:03 AM
DateCompanyBrokerageAction
3/2/2021Atara BiotherapeuticsWilliam BlairReiterated Rating
3/2/2021Atara BiotherapeuticsCitigroupUpgrade
12/9/2020Atara BiotherapeuticsSmith Barney CitigroupDowngrade
12/9/2020Atara BiotherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngrade
12/8/2020Atara BiotherapeuticsHC WainwrightReiterated Rating
12/7/2020Atara BiotherapeuticsStifel NicolausBoost Price Target
11/23/2020Atara BiotherapeuticsMizuhoBoost Price Target
9/14/2020Atara BiotherapeuticsCanaccord GenuityBoost Price Target
6/30/2020Atara BiotherapeuticsEvercore ISIInitiated Coverage
5/12/2020Atara BiotherapeuticsJPMorgan Chase & Co.Boost Price Target
12/10/2019Atara BiotherapeuticsCowenReiterated Rating
1/15/2021AlectorBank of AmericaInitiated Coverage
7/29/2020AlectorBarclaysLower Price Target
6/4/2020AlectorMorgan StanleyBoost Price Target
4/28/2020AlectorThe Goldman Sachs GroupInitiated Coverage
11/27/2019AlectorBTIG ResearchInitiated Coverage
3/4/2019AlectorSVB LeerinkInitiated Coverage
2/3/2021ImmunovantRaymond JamesLower Price Target
2/2/2021ImmunovantCredit Suisse GroupDowngrade
11/13/2020ImmunovantTruistBoost Price Target
11/13/2020ImmunovantRobert W. BairdBoost Price Target
11/12/2020ImmunovantChardan CapitalBoost Price Target
10/28/2020ImmunovantUBS GroupInitiated Coverage
10/12/2020ImmunovantGuggenheimInitiated Coverage
10/6/2020ImmunovantLifesci CapitalReiterated Rating
10/2/2020ImmunovantCSFBInitiated Coverage
3/18/2021Forma TherapeuticsOppenheimerReiterated Rating
12/8/2020Forma TherapeuticsCantor FitzgeraldBoost Price Target
7/14/2020Forma TherapeuticsJefferies Financial GroupInitiated Coverage
8/14/2020VaxcyteNeedham & Company LLCReiterated Rating
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.